

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Piet HERDEWIJN et al.	Confirmation No.:	6995
Serial No.:	10/598,535	Art Unit:	1623
371 (c) Date:	September 1, 2006	Examiner:	Lawrence E. Crane
Customer No.:	21559		
Title:	PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after the mailing of a Notice of Allowance, but before payment of the issue fee. I, the undersigned, hereby certify that the item of information is in a communication from a foreign patent office in a counterpart foreign application, mailed June 28, 2011, which is not more than three months prior to the filing of this statement. This communication was also not received by any individual designated in 37 C.F.R. 1.56(c) more than thirty days prior to the filing of this information disclosure statement. Please charge \$180.00 to Deposit Account No. 03-2095 in payment of the fee required by 37 C.F.R. § 1.17(p).

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 7/27/2011



James D. DeCamp
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045